MedPage Today April 3, 2024
— Phase II study of GLP-1 drug lixisenatide meets primary endpoint
The glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Adlyxin) led to less progression of motor disability compared with placebo in early Parkinson’s disease, the phase II LIXIPARK trial showed.
At 12 months, motor scores on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III improved by 0.04 points in the lixisenatide group and worsened by 3.04 points in the placebo group, a difference of 3.08 points (95% CI 0.86-5.30, P=0.007), reported Olivier Rascol, MD, PhD, of the University of Toulouse in France, and co-authors.
Nausea occurred in 46% and vomiting in 13% of lixisenatide-treated participants, the researchers said in the New England Journal of Medicine. Secondary endpoint results...
Today's Sponsors
Today's Sponsor